Twenty-nine of the 48 novel drug approvals of 2019, or 60%, were designated in one or more expedited categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.
Alembic's generic Temovate provides a short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Venlafaxine ER tablets, 150 mg and 225 mg, and lidocaine topical solution 4% had a market value of roughly $150 million and $17 million, respectively, for the 12 months ended November 2019.